US2022054497A1PendingUtilityA1
PREVENTION OF ATHEROSCLEROTIC EVENTS WITH DIRECT FACTOR Xa INHIBITORS
Est. expiryApr 15, 2036(~9.7 yrs left)· nominal 20-yr term from priority
A61K 31/5377A61K 31/44A61K 9/20A61K 31/437A61K 31/4427A61K 31/444A61P 43/00A61K 31/4365A61K 31/4425A61P 9/10A61K 31/4545
57
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The use of direct factor Xa inhibitors, administered in a dose sufficient to reduce the activity of factor Xa to about 25% less than normal or lower, has the effect of preventing the onset of atherosclerosis, and stabilizing atherosclerotic lesions, and preventing the occurrence or recurrence of atherosclerotic events.
Claims
exact text as granted — not AI-modified1 . A method of reducing the likelihood of developing atherosclerosis in a human, comprising: measuring factor Xa activity in a patient, and administering an inhibitor of factor Xa in an amount effective to reduce activity of factor Xa by 25% or more in a patient having a measured normal factor Xa activity.
Join the waitlist — get patent alerts
Track US2022054497A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.